NL-OMON32383已完成3 期
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin*s Lymphoma (NHL), Hodgkin*s Disease (HD) or Multiple Myeloma (MM) * Safety Study in a General Autologous Transplant Population - MOZ00808
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Genzyme
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Diagnosis of MM, NHL, or HD in partial response (PR) or complete response (CR)
- •2.Eligible and planned for an autologous haematopoietic stem cell transplantation
- •4.At least 18 years of age (inclusive)
排除标准
- •1. History of any acute or chronic leukaemia (including myelodysplastic syndrome)
- •2. Prior allogeneic transplantation or more than one prior autologous transplantation
- •3. Failed previous CD34+ cell collection attempts (either due to insufficient yield in apheresis product, or ineligible for apheresis because of inadequate mobilisation of CD34+ cells into peripheral blood)
- •4. Less than 4 weeks since last anti-cancer therapy (including chemotherapy, biologic/immunologic, radiation) or less than 6 weeks if prior therapy with nitrosourea or mitomycin (for therapies with long-acting agents, a treatment-free interval of at least 2 half-lives should be considered) with the exception of
- •- Treatment with thalidomide, dexamethasone, lenalidomide (Revlimid*), and/or bortezomib (Velcade*) which is allowed up to 7 days prior to the first dose of G-CSF.
研究者
相似试验
进行中（未招募）
不适用
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioMobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 9.1Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000689-21-DEGenzyme Europe BV
进行中（未招募）
不适用
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioEUCTR2008-000689-21-NLGenzyme Europe BV
进行中（未招募）
不适用
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin?s Lymphoma (NHL), Hodgkin?s Disease (HD) or Multiple Myeloma (MM) ? Safety Study in a General Autologous Transplant Population - NDMobilisation of peripheral blood stem cells prior autologous stem cell transplantation in patients with Non-Hodgkin?s Lymphoma (NHL), Hodgkin?s Disease (HD) or Multiple Myeloma (MM)MedDRA version: 9.1Level: PTClassification code 10020206MedDRA version: 9.1Level: PTClassification code 10029547MedDRA version: 9.1Level: PTClassification code 10028228EUCTR2008-000689-21-ITGenzyme Europe BV100
进行中（未招募）
不适用
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioMobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 9.1Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000689-21-GBGenzyme Europe BV
进行中（未招募）
不适用
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioMobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 9.1Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000689-21-SEGenzyme Europe BV100